Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... February 4, 2020 38% of Recurrent Breast Cancers Have a Different HER2 Status than... May 25, 2021 Woman Who Died For 27 Minutes Shares Haunting Message When Revived August 12, 2019 EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Load more HOT NEWS Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... Lo que debe saber sobre el cáncer de pulmón How erectile dysfunction drugs could be the key to overcoming treatment... More Immunotherapy Options Approved for Treating Endometrial Cancer
